For research use only. Not for therapeutic Use.
Briakinumab（Cat No.:I042151）is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), two cytokines involved in the immune system’s inflammatory response. By blocking these cytokines, Briakinumab aims to reduce inflammation and is primarily investigated for the treatment of inflammatory conditions like psoriasis, Crohn’s disease, and other autoimmune disorders. IL-12 and IL-23 play a significant role in the development of certain chronic inflammatory diseases, and Briakinumab has shown promise in clinical trials as a treatment option for controlling symptoms and improving patients’ quality of life.
| Catalog Number | I042151 |
| CAS Number | 339308-60-0 |
| Purity | ≥95% |
